Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B
Take care of yourself by scheduling regular physician appointments to monitor your chronic hepatitis B
The natural history of chronic hepatitis B
Results: Serum total protein levels were within the normal range in both Chronic Hepatitis B
patients and controls with mean value of 6.
Chronic hepatitis B
and C cause thousands of cases of liver cancer, liver disease, and death each year--taking the heaviest toll among Asians, Pacific Islanders, and blacks in the United States.
The work, which Aach calls "the most promising approach to date," does not prove absolutely that the combination treatment can cure chronic hepatitis B
, both Aach and the researchers point out, because of the short follow-up period.
These populations have the highest rates of chronic hepatitis B
among all racial/ethnic groups in the United States and also a disproportionately high risk for liver cancer.
Schaefer Price, Pharmasset's president & CEO, stated, "As new, better therapies are introduced into the HBV market, we believe the market will grow and the standard of care for the treatment of chronic Hepatitis B
will evolve into a combination therapy similar to HAART therapy used to combat HIV.
The indication for Hepsera recommended by the CPMP is for the treatment of chronic hepatitis B
in adults with compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and fibrosis; or decompensated liver disease.
Valeant licensed pradefovir from Metabasis in 2000 and has been conducting clinical trials to evaluate the safety and efficacy of pradefovir for the treatment of compensated chronic hepatitis B
The application is supported by data from Phase III studies in hepatitis B "e" antigen-positive patients, hepatitis B "e" antigen-negative patients and chronic hepatitis B
patients with lamivudine-resistant HBV.
PEGASYS is the only pegylated interferon indicated for the treatment of adult patients with chronic hepatitis B
(HBeAg positive and HBeAg negative chronic hepatitis B
who have compensated liver disease and evidence of viral replication and liver inflammation).
TSX:VIR)(AMEX:REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B
& C and embolotherapy treatments for tumors, today announced that it has entered into a research collaboration with Defence Research and Development Canada - Suffield (DRDC Suffield) to carry out research on applying ViRexx's proprietary Chimigen(TM) vaccine platform for biodefense.
The study will primarily evaluate the safety and tolerability of the HBV immunotherapeutic, pdpSC18, administered by PMED(TM), PowderMed's needle-free delivery technology, in patients with chronic Hepatitis B
infection, both in combination with lamivudine and as monotherapy.
TSX:VIR) (AMEX:REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B
and C and embolotherapy treatments for tumors, announced today that the Company's President, Marc Canton, was interviewed on March 23rd, 2006 by the Zangani Investor Community.